Literature DB >> 25424803

Fast vaccine design and development based on correlates of protection (COPs).

Cécile van Els1, Siri Mjaaland, Lisbeth Næss, Julia Sarkadi, Eva Gonczol, Karen Smith Korsholm, Jon Hansen, Jørgen de Jonge, Gideon Kersten, Jennifer Warner, Amanda Semper, Corine Kruiswijk, Fredrik Oftung.   

Abstract

New and reemerging infectious diseases call for innovative and efficient control strategies of which fast vaccine design and development represent an important element. In emergency situations, when time is limited, identification and use of correlates of protection (COPs) may play a key role as a strategic tool for accelerated vaccine design, testing, and licensure. We propose that general rules for COP-based vaccine design can be extracted from the existing knowledge of protective immune responses against a large spectrum of relevant viral and bacterial pathogens. Herein, we focus on the applicability of this approach by reviewing the established and up-coming COPs for influenza in the context of traditional and a wide array of new vaccine concepts. The lessons learnt from this field may be applied more generally to COP-based accelerated vaccine design for emerging infections.

Entities:  

Keywords:  COP based vaccine design; correlates of protection; influenza; vaccine development

Mesh:

Substances:

Year:  2014        PMID: 25424803      PMCID: PMC4186026          DOI: 10.4161/hv.28639

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  143 in total

1.  Clinical and immunologic predictors of influenza illness among vaccinated older adults.

Authors:  Zainab Shahid; Alison Kleppinger; Beth Gentleman; Ann R Falsey; Janet E McElhaney
Journal:  Vaccine       Date:  2010-07-31       Impact factor: 3.641

2.  Registration of influenza vaccines for children in Europe.

Authors:  Marta Granström; Albertha C G Voordouw
Journal:  Vaccine       Date:  2011-08-04       Impact factor: 3.641

3.  Universal influenza vaccine: the holy grail?

Authors:  Alan R Shaw
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

4.  Pathogenesis of Influenza A/H5N1 virus infection in ferrets differs between intranasal and intratracheal routes of inoculation.

Authors:  Rogier Bodewes; Joost H C M Kreijtz; Geert van Amerongen; Ron A M Fouchier; Albert D M E Osterhaus; Guus F Rimmelzwaan; Thijs Kuiken
Journal:  Am J Pathol       Date:  2011-05-05       Impact factor: 4.307

5.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

6.  Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.

Authors:  R B Belshe; W C Gruber; P M Mendelman; H B Mehta; K Mahmood; K Reisinger; J Treanor; K Zangwill; F G Hayden; D I Bernstein; K Kotloff; J King; P A Piedra; S L Block; L Yan; M Wolff
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

7.  Live attenuated versus inactivated influenza vaccine in infants and young children.

Authors:  Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Micki Hultquist; George Kemble; Edward M Connor
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

8.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

9.  Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans.

Authors:  Wendy Peters; Jennifer R Brandl; Jonathan D Lindbloom; C Josefina Martinez; Ciaran D Scallan; George R Trager; Debora W Tingley; Martin L Kabongo; Sean N Tucker
Journal:  Vaccine       Date:  2013-01-25       Impact factor: 3.641

Review 10.  Making better influenza virus vaccines?

Authors:  Peter Palese
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

View more
  7 in total

1.  Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial.

Authors:  Renée A J van Boxtel; Pauline Verdijk; Otto J de Boer; Elly van Riet; Tjeert T Mensinga; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Distinguishing Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines.

Authors:  Wey Wen Lim; Nancy H L Leung; Sheena G Sullivan; Eric J Tchetgen Tchetgen; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2020-03-02       Impact factor: 4.897

Review 3.  Development of cross-protective influenza a vaccines based on cellular responses.

Authors:  Peter Christiaan Soema; Elly van Riet; Gideon Kersten; Jean-Pierre Amorij
Journal:  Front Immunol       Date:  2015-05-15       Impact factor: 7.561

Review 4.  Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.

Authors:  Pengfei Jin; Jingxin Li; Hongxing Pan; Yanfei Wu; Fengcai Zhu
Journal:  Signal Transduct Target Ther       Date:  2021-02-02

5.  Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients.

Authors:  Xunyan Ye; Obinna P Iwuchukwu; Vasanthi Avadhanula; Letisha O Aideyan; Trevor J McBride; David M Henke; Kirtida D Patel; Felipe-Andres Piedra; Laura S Angelo; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra
Journal:  Viruses       Date:  2021-05-26       Impact factor: 5.048

6.  The Kaposi's Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals.

Authors:  Yasaman Mortazavi; Salum J Lidenge; Tara Tran; John T West; Charles Wood; For Yue Tso
Journal:  Viruses       Date:  2020-02-26       Impact factor: 5.048

Review 7.  Malaria vaccines: facing unknowns.

Authors:  Nirianne Marie Q Palacpac; Toshihiro Horii
Journal:  F1000Res       Date:  2020-04-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.